Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 5, pp 137–145 | Cite as

Enzyme-replacement therapy: Problems and prospects

  • B. Rademaker
  • J. Raber
Review Articles

Abstract

Several diseases can, at least in theory, be treated by the administration of an enzyme, the deficiency of which is the cause of the disease. Various attempts have been made to correct enzymatic deficiencies responsible for the clinical manifestation of diseases for which prevention cannot be achieved by modification of the diet or by supportive therapy with drugs. Except for treating certain digestive disorders, enzyme-replacement therapy has not yet found a broad application. In this review article a compilation is given of the problems and prospects of enzyme-replacement therapy in diseases caused by the deficiency of an enzyme.

Keywords

Deficiency diseases Enzymes Lysosomes Replacement therapy Transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barton RW, Neufeld ER. The Hurler corrective factor. J Biol Chem 1971;24:7773–9.Google Scholar
  2. 2.
    Myerowitz R, Neufeld EF. Maturation ofα-l-iduronidase in cultured human fibroblasts. J Biol Chem 1981; 256:3044–8.PubMedGoogle Scholar
  3. 3.
    Bach G, Neufeld EF. Synthesis and maturation of crossreactive glycoprotein in fibroblasts deficient in arylsulfatase A activity. Biochem Biophys Res Commun 1983; 112:198–205.PubMedGoogle Scholar
  4. 4.
    Prioa RL, Neufeld EF. Synthesis ofβ-hexosaminidase in cell-free translation and in intact fibroblasts. An insoluble precursorα-chain in a rare form of Tay-Sachs disease. Proc Natl Acad Sci USA 1982;79:6360–4.PubMedGoogle Scholar
  5. 5.
    Inui K, Emmett M, Wenger DA. Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy. Proc Natl Acad Sci USA 1983;80:3074–7.PubMedGoogle Scholar
  6. 6.
    D'Azzo A, Hoogeveen A, Reuser AJJ, Robinson D, Galjaard H. Molecular defect in combinedβ-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci USA 1982;79:4535–9.PubMedGoogle Scholar
  7. 7.
    Von Figura K, Hasilik A. Genesis of lysosomal enzyme deficiencies. TiBS 1984;9:29–31.Google Scholar
  8. 8.
    Adinolphi M, Brown S. Strategies for the correction of enzymatic deficiencies in patients with mucopolysaccharidoses. Dev Med Child Neurol 1984;26:404–8.PubMedGoogle Scholar
  9. 9.
    Scaggiante B, Pineschi A, Sustersich M, Andolina M, Agosti E, Romeo D. Successful therapy of NiemannPick disease by implantation of human amniotic membrane. Transplantation 1987;44:59–61.PubMedGoogle Scholar
  10. 10.
    Adinolfi M, Akle CA, McColl I, et al. Expression of HLA antigensβ2-microglobulin and enzymes by human amniotic epithelial cells. Nature 1982;295: 325–7.PubMedGoogle Scholar
  11. 11.
    Robbins AR, Myerowitz R. The mannose 6-phosphate receptor of Chinese hamster ovary cells. J Biol Chem 1981;256:10623–7.PubMedGoogle Scholar
  12. 12.
    Zitelli BJ, Malatack JJ, Gartner JC, Shaw BW, Iwatsuki S, Starzl TE. Orthotopic liver transplantation in children with hepatic-based metabolic disease. Transplant Proc 1983;15:1284–7.Google Scholar
  13. 13.
    Malatack JJ, Iwatsuki S, Gartner JC, et al. Liver transplantation for type I glycogen storage disease. Lancet 1983;1:1073–8.PubMedGoogle Scholar
  14. 14.
    Groth CG, Ringden O. Transplantation in relation to the treatment of inherited disease. Transplantation 1984;38:319–27.PubMedGoogle Scholar
  15. 15.
    Hoogerbrugge PM, Poorthuis BJHM, Mulder AH, et al. Correction of lysosomal enzyme deficiency in various organs ofβ-glucuronidase-deficient mice by allogeneic bone marrow transplantation. Transplantation 1987; 43:609–14.PubMedGoogle Scholar
  16. 16.
    Parkman R. The application of bone marrow transplantation to the treatment of genetic diseases. Science 1986;232:1373–8.PubMedGoogle Scholar
  17. 17.
    Krivit W, Whithley CB. Bone marrow transplantation for genetic diseases. N Engl J Med1984;316:1085–7.Google Scholar
  18. 18.
    Hobbs JR, Jones H, Barret AJ, et al. Reversal of clinical features of Hurler's disease and. biochemical improvement after treatment by bone marrow transplantation. J Inherited Metab Dis 1982;5:59–60.PubMedGoogle Scholar
  19. 19.
    Bayever E, Ladish S, Philippart M, et al. Bone-marrow transplantation for metachromatic leucodystrophy. Lancet 1985;2:471–3.PubMedGoogle Scholar
  20. 20.
    Rappeport JM, Ginns EI. Bone marrow transplantation in severe Gaucher's disease. N Engl J Med 1984; 311:84–8.PubMedGoogle Scholar
  21. 21.
    Erikson A. Gaucher disease: Norrbottnian type (III). Acta Paediatr Scand1986;(Suppl 326):1–42.Google Scholar
  22. 22.
    Beaudet AL. Gaucher's disease. N Engl J Med 1987; 316:619–21.PubMedGoogle Scholar
  23. 23.
    Choudary PV, Barranger JA, Tsujc S, et al. Retrovirus mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts. Mol Biol Med 1986;3: 293–9.PubMedGoogle Scholar
  24. 24.
    Gasper PW, Thrall MA, Wenger DA, et al. Correction of feline arylsulphatase B deficiency (mucopolysaccharidosis VI) by bone marrow transplantation. Nature 1984;312:467–9.PubMedGoogle Scholar
  25. 25.
    Krivit W, Pierpont ME, Ayaz K, et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidasis type VI). N Engl J Med 1984; 311:1606–11.PubMedGoogle Scholar
  26. 26.
    Taylor RM, Stewart GJ, Farrow BRH, Healy PJ. Enzyme replacement in nervous tissue after allogeneic bone-marrow transplantation for fucosidosis in dogs. Lancet 1986;2:772–4.PubMedGoogle Scholar
  27. 27.
    Hoogerbrugge PM, Poorthuis BJHM, Mulder AH, et al. Correction of lysosomal enzyme deficiency in various organs ofβ-glucuronidase-deficient mice by allogeneic bone marrow transplantation. Transplantation 1987; 43:609.PubMedGoogle Scholar
  28. 28.
    Bartlett PF. Pluripotential hemopoietic stem cells in adult mouse brain. Proc Natl Acad Sci USA 1982;79: 2722–5.PubMedGoogle Scholar
  29. 29.
    Hoogerbrugge PM, Wagemaker G, Van Bekkum DW. Failure to demonstrate pluripotential hemapoietic stem cells in mouse brain. Proc Natl Acad Sci USA 1985;82:4268–9.PubMedGoogle Scholar
  30. 30.
    Yaeger AM, Brennan S, Tiffany C, Moser HW, Santos GW. Prolonged survival and remyelination after hematopoietic cell transplantation in the Twitcher mouse. Science 1984;225:1052–4.PubMedGoogle Scholar
  31. 31.
    Ichioka T, Kishimoto Y, Brennan S, Santos GW, Yeager AM. Hematopoietic cell transplantation in murine globoid cell leukodystrophy (the twitcher mouse). Effects on levels of galactosylceramidase, psychosine and galactocerebrosides. Proc Natl Acad Sci USA 1987;84: 4259–63.PubMedGoogle Scholar
  32. 32.
    Scaravilli F, Jacobs JM. Improved myelination in nerve grafts from the leukodystrophic twitcher into trembler mice: evidence for enzyme replacement. Brain Res 1982;237:163–72.PubMedGoogle Scholar
  33. 33.
    Scaraville F, Suzuki K. Enzyme replacement in grafted nerve of twitcher mouse. Nature 1983;305:713–5.PubMedGoogle Scholar
  34. 34.
    Barranger JA. Access of enzymes to brain following osmotic alteration of the blood-brain barrier. In: Desnick RJ, ed. Enzyme therapy in genetic diseases. Vol. 2. New York: Liss, 1980:195–205.Google Scholar
  35. 35.
    Neuwelt EA, Barranger JA, Brady RO, et al. Delivery of hexosaminidase A to cerebrum after osmotic modification of the blood-brain barrier. Proc Natl Acad Sci USA 1981;78:5838–41.PubMedGoogle Scholar
  36. 36.
    Ratazzi MC, Lanse SB, McCullough RAM, Nester JA, Jacobs EA. Towards enzyme replacement in GM2 gangliosidosis: organ disposition and induced central nervous system uptake of humanβ-hexosaminidase in the cat. In: Desnick RJ, ed. Enzyme therapy in genetic diseases. Vol. 2. New York: Liss, 1980:179–93.Google Scholar
  37. 37.
    Kusiak JW, Quirk JM, Brady RO. Specific binding ofβ- hexosaminidase A to rat brain synaptic plasma membranes. In: Desnick RJ, ed. Enzyme therapy in genetic diseases. Vol. 2. New York: Liss, 1980:93–102.Google Scholar
  38. 38.
    Fisher HD, Gonzalez-Noriega A, Sly WS, Morré DJ. Phosphomannosyl-enzyme receptors in rat liver. J Biol Chem 1980;255:9608–9.PubMedGoogle Scholar
  39. 39.
    Osada T, Kuroda Y, Ikai A. Endocytotic internalization ofα-2-macroglobulin:α-galactosidase conjugate by cultured fibroblasts derived from Fabry hemizygote. Biochem Biophys Res Commun 1987;142:100–6.PubMedGoogle Scholar
  40. 40.
    Nishigai M, Osada T, Akai A. Structural changes in alpha-2 macroglobulin and ovomacroglobulen studied by gel chromatography and electron microscopy. Biochim Biophys Acta 1985;831:236–41.PubMedGoogle Scholar
  41. 41.
    Osada T, Kuroda Y, Ikai A. The fate of internalizedα-2-macroglobulin:α-galactosidase conjugate in fibroblasts from Fabry's hemizygote. Biochem Biophys Res Commun 1987;143:954–8.PubMedGoogle Scholar
  42. 42.
    Salvesen GS, Sayers CA, Barrett AJ. Further characterization of the covalent linking reaction ofα 2-macroglobulin. Biochem J 1981;195:453–61.PubMedGoogle Scholar
  43. 43.
    Hasholt L, Sorensen SA. Con A-mediated binding and uptake of purifiedα-galactosidase A in Fabry fibroblasts. Exp Cell Res 1983;148:405–11.PubMedGoogle Scholar
  44. 44.
    Goldman R, Raz A. Concanavalin A and thein vitro induction in macrophages of vacuolation and lysosomal enzyme synthesis. Exp Cell Res 1975;96:393–405.PubMedGoogle Scholar
  45. 45.
    Poretz RD, Triemer RE, St. John AC, et al. Lectininduced accumulation of large lysosomis in cultured fibroblasts. Exp Cell Res 1980;128:133–42.PubMedGoogle Scholar
  46. 46.
    Hasholt L, Wandall A, Sorensen SA. Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopal studies. Clin Genet 1988;33:360–71.PubMedGoogle Scholar
  47. 47.
    Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981;673:425–34.PubMedGoogle Scholar
  48. 48.
    Furbish FS. Molecular basis of lysosomal storage disorders. New York: Academic Press, 1984:219.Google Scholar
  49. 49.
    Murray GJ, Doebber TW, Shen TY, et al. Targeting of synthetically glycosylated human placental glucocerebrosidase. Biochem Med 1985;34:241–6.PubMedGoogle Scholar
  50. 50.
    Reuser AJJ, Kroos MA, Ponne MJ, et al. Uptake and stability of human and bovine acidα-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenesis type II patients. Exp Cell Res 1984;155: 178–89.PubMedGoogle Scholar
  51. 51.
    Di Marco PN, Howell JMcC, Darling PR, Taylor EG. Bovine generalized glycogenesis type II. A descriptive review of the syndrome and discussion of its treatment. Isr J Vet Med 1987;43:162–72.Google Scholar
  52. 52.
    Howell JMcC, Darling PR, Di Marco PN, Taylor EG. Multiple implantation of normal amnion into cattle with generalized glycogenesis type II. J Inherited Metab Dis 1987;10:3–10.Google Scholar
  53. 53.
    Rosenfeld EL, Belenky DM, Bystrova NK. Interaction of hepatic asialoglycoprotein receptor with asialoorosomucoid and galactolyzed lysosomalα-glucosidase. Biochim Biophys Acta 1986;883:306–12.PubMedGoogle Scholar
  54. 54.
    Poules A, Ranieri E, Shankaren P, Callahan JW. Studies on the activation of the enzymatic hydrolysis of sphingomyelin liposomes. Biochim Biophys Acta 1984;793:141–8.PubMedGoogle Scholar
  55. 55.
    Choy FYM. Gaucher disease: the effects of phosphatidylserine of glucocerebrosidase from normal and Gaucher fibroblasts. Hum Genet 1984;67:432–6.PubMedGoogle Scholar
  56. 56.
    Poules A, Shankaran P, Jones CS, Callahan JW. Enzymatic hydrolysis of sphingomyelin liposomes by normal tissues and tissues from patients with Niemann-Pick disease. Biochim Biophys Acta 1983;751:428–33.PubMedGoogle Scholar
  57. 57.
    Datta SC, Radin NS. Physiological control of the level of sphingolipid hydrolase stimulating protein, CHS-I. Fed Proc 1985;44:1090.Google Scholar
  58. 58.
    Datta SC, Snider RM, Radin NS. Uptake by neuroblastoma cells of glucosylceramide, glucosylceramide glucosidase, its stimulator protein, and phosphatidylserine. Biochim Biophys Acta 1986;877:387–98.PubMedGoogle Scholar
  59. 59.
    Bridges K, Harford J, Ashwell G, Klausner RD. Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci USA 1982;79:350–4.PubMedGoogle Scholar
  60. 60.
    Wiley HS, Cunningham DD. A steady-state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands. Cell 1981;25: 433–40.PubMedGoogle Scholar
  61. 61.
    Taylor ME, Leaning MS, Summerfield JA. Uptake and processing of glycoproteins by rat hepatic mannose receptor. Am J Physiol 1978;252:690–8.Google Scholar
  62. 62.
    Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316:589–95.PubMedGoogle Scholar
  63. 63.
    Kredich NM, Hershfield MS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phospherylase deficiency. In: The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill, 1982:1157–83.Google Scholar
  64. 64.
    Schmalstieg FC, Mills GC, Nelson JA, May LT, Goldman AS, Goldblum RM. Limited effect of erythrocyte and plasma infusions in adenosine deaminase deficiency. J Pediatr 1978;93:597–603.PubMedGoogle Scholar
  65. 65.
    Chen RHL, Abuchowski A, Van Es T, Palczuk NC, Davis FF. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim Biophys Acta 1981;660:293–8.PubMedGoogle Scholar
  66. 66.
    Sato P, Lindemann D. Adaptability of an enzyme replacement therapy to other enzymes with potential therapeutic applications. J Appl Biochem 1985;7: 323–31.PubMedGoogle Scholar
  67. 67.
    La Du BN. Metabolic basis of inherited disease. Histidinemia. New York: McGraw-Hill, 1978:317.Google Scholar
  68. 68.
    Rich KC, Mejias E, Fox IH. Purine nucleoside phosphorylase deficiency: improved metabolic and immunologic function with erythrocyte transfusions. N Engl J Med1980;303:973–7.PubMedGoogle Scholar
  69. 69.
    Paillot B, Remy M-H, Thomas D, Brown G. Soluble cross-linked enzyme polymers. Some physicochemical properties. Pathol Biol 1974;22:491–5.Google Scholar
  70. 70.
    Yagura T, Kamisaki Y, Wada H, Yamamura Y. Immunological studies on modified enzymes. Arch Allergy App Immunol 1981;64:11–8.Google Scholar
  71. 71.
    Pornansky MJ. Enzyme-protein conjugates: new possibilities for enzyme therapy. Pharmacol Ther 1983;21: 53–76.PubMedGoogle Scholar
  72. 72.
    Bourget L, Chang TMS. Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria. FEBS Lett 1985;180:5–8.PubMedGoogle Scholar
  73. 73.
    Kanalas JJ, Spector EB, Cederbaum SD. Hollow-fiber reactors containing mammalian arginase. An approach to enzyme replacement therapy. Biochem Med1982;27: 46–55.PubMedGoogle Scholar
  74. 74.
    Espinola LG, Wider EA, Stella AM, Battle AM del C. Enzyme replacement therapy in porphyrias. II. Entrapment ofδ-aminolaevulinate dehydratase in liposomes. Int J Biochem 1983;15:439–45.Google Scholar
  75. 75.
    Staal GE, Stoop JW, Zegers BJM, et al. Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes. J Clin Invest 1980;65:103–8.PubMedGoogle Scholar
  76. 76.
    Endo F, Matsuda I, Ogata A, Tamaka S. Human erythrocyte prolidase and prolidase deficiency. Pediatr Res 1982;16:227–31.PubMedGoogle Scholar
  77. 77.
    Sagiyama T, Nakabayashi H, Shimusa H, Hondo W, Kodama S, Kitagawa T. A successful trial of enzyme replacement therapy in a case of argininemia. Tohoku J Exp Med 1984;142:239–48.PubMedGoogle Scholar
  78. 78.
    Adriaenssens K, Karcher D, Marescau B, Van Broeckhoven C, Lowenthal A, Terheggen HC. Hyperargininemia: the rat as a model for the human disease and the comparitive response to enzyme replacement therapy with free arginase and arginase loaded erythrocytesin vivo. Int J Biochem 1984;16:779–86.PubMedGoogle Scholar
  79. 79.
    Mizutani N, Hayakawa C, Machara M, Watanabe K. Enzyme replacement therapy in a patient with hyperargininemia. Tohoku J Exp Med 1987;151:301–7.PubMedGoogle Scholar
  80. 80.
    Edwards NL, Jerye W, Fox IH. Enzyme replacement in the Lesch-Nyhan Syndrome with long term erythrocyte transfusions. Adv Exp Med Biol 1984;165:23–6.PubMedGoogle Scholar
  81. 81.
    Battle AM del C, Bustos NL, Stella AM, Wider EA, Conti HA, Mendez A. Enzyme replacement therapy in porphyrias. IV. First successful human clinical trial ofδ-aminolevulinate dehydratase-loaded erythrocyte ghosts. Int J Biochem 1983;15:1261–5.PubMedGoogle Scholar
  82. 82.
    Bustus NL, Stella AM, Wider EA, Battle AM del C. Enzyme replacement therapy in porphyrias. III. Potential use of erythrocyte ghosts as carriers ofδ-aminolaevulinate dehydratase. Int J Biochem 1983;15:447–52.Google Scholar
  83. 83.
    Whyte MP, McAlister WH, Patton LS, et al. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma. Results in three additional patients. J Pediatr 1984;105:926–33.PubMedGoogle Scholar
  84. 84.
    Wilkinson MR, Wagstaffe C, Delbridge L, Wiseman J, Posen S. Serum osteocalcin concentrations in Paget's disease of bone. Arch Intern Med 1986;146:268–71.PubMedGoogle Scholar
  85. 85.
    Brocklehurst D, Wilde CE. Evidence for the hormonal regulation of the multimolecular forms of serum alkaline hosphatase. In: Stigbrand T, ed. Human alkaline phosphatase. New York: Liss, 1984:277–88.Google Scholar
  86. 86.
    Albeggiani A, Cataldo F. Infantile hypophosphatasia diagnosed at 4 months and surviving at 2 years. Helv Paediatr Acta 1982;37:49–59.PubMedGoogle Scholar
  87. 87.
    Whyte MP, Magill HL, Fallon MD, Herrod HG. Infantile hypophosphatasia. Normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. J Pediatr 1986;108:82–8.PubMedGoogle Scholar
  88. 88.
    Macpherson RI, Kroeker M, Houston CS. Hypophosphatasia. J Can Assoc Radiol 1972, 23:16–26.PubMedGoogle Scholar
  89. 89.
    Newcomer AD. Milk, lactase and gene distribution. Am J Dig Dis 1978;23:961–2.PubMedGoogle Scholar
  90. 90.
    Rosado JL, Solomons NW, Lisker R, Bourges H. Enzyme replacement therapy for primary adult lactase deficiency. Gastroenterology 1984;87:1072–82.PubMedGoogle Scholar
  91. 91.
    Biller JA, King S, Rosenthal A, Grand RJ. Efficacy of lactase-treated milk for lactose-intolerant pediatric patients. J Pediatr 1987;111:91–4.PubMedGoogle Scholar
  92. 92.
    Moskovitz M, Curtis C, Gavaler J. Does oral enzyme replacement therapy reverse intestinal lactose malabsorption? Am J Gastroenterol 1987;82:632–5.PubMedGoogle Scholar
  93. 93.
    Kolars JC, Levitt MD, Aouji M, Savaiano DA. Yoghurt — an autodigesting source of lactose. N Engl J Med 1984;310:1–3.PubMedGoogle Scholar
  94. 94.
    DiMagno ER, Go VLW, Summerskill WHJ. Relation between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973;288:813–5.PubMedGoogle Scholar
  95. 95.
    Saunders JHB, Wormsley KG. Progress report. Pancreatic extracts in the treatment of pancreatic exocrine insufficiency. Gut 1975;16:257–61.Google Scholar
  96. 96.
    Lankisch PG, Creutzfeldt W. Therapy of exocrine and endocrine pancreatic insufficiency. Clin Gastroenterol 1984;13:985–99.PubMedGoogle Scholar
  97. 97.
    Pap A, Varro V. Replacement therapy in pancreatic insufficiency with new pancreatic preparation respecting the physiological ratio of lipase/trypsin activity. Hepatogastroenterology 1988;35:83–6.PubMedGoogle Scholar
  98. 98.
    Stern M, Plettner C, Grüttner R. Pancreatic enzyme replacement therapy in cystic fibrosis (CF). Klin Pädiatr 1988;200:36–9.Google Scholar
  99. 99.
    Whitehead AM. Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations. Pharm Weekbl [Sci] 1988;10:12–6.Google Scholar
  100. 100.
    Cleghorn GJ, Shephard RW, Holt TL. The use of a synthetic prostaglandin E1 analogue (misoprostol) as an adjunct to pancreatic enzyme replacement in cystic fibrosis. Scand J Gastroenterol 1988;23:142–7.Google Scholar
  101. 101.
    Lamers CBHW, Jansen JBMJ. Omeprazole as adjunct to enzyme replacement treatment in severe pancreatic insufficiency. Br Med J 1986;293:994.Google Scholar
  102. 102.
    Durie PR, Bell L, Linton W, et al. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut1980;21:778–86.PubMedGoogle Scholar
  103. 103.
    Pool JG, Shannon AE. Production of high-potency concentrates of anti-haemophilia globulin in a closed bag system. N Engl J Med 1965;273:1443–7.PubMedGoogle Scholar
  104. 104.
    Proose CV, McGill A. Evaluation of the Mason (continous-thaw-siphon) method for cryoprecipitate production. Vox Sang 1979;37:235–43.PubMedGoogle Scholar
  105. 105.
    Levy JA, Mitra G, Mozen MM. Recovery and inactivation of infectious retroviruses added to factor VIII concentrates. Landt 1984;2:722–3.Google Scholar
  106. 106.
    Kuratsuji T, Oikawa T, Fukamoto T, et al. Factor XIII deficiency in antibiotic-associated pseudomembranous colitis and its treatment with factor XIII concentrate. Haemostosis 1982;11:229–34.Google Scholar
  107. 107.
    Larrieu MJ, Caen J, Soulier JP, Bernard J. Treatment of haemophilia B with a plasma fraction rich in the antihaemophilia B factor (PPSB). Pathol Biol 1959;7: 2507–13.PubMedGoogle Scholar
  108. 108.
    Faria R, Fiumara N. Hepatitis B associated with Konyne. N Engl J Med 1972;287:358–9.Google Scholar
  109. 109.
    Trepo C, Hantz D, Jacquier MF, et al. Different fates of hepatitis B virus markers during plasma fractionation. Vox Sang 1978;35:143–8.PubMedGoogle Scholar
  110. 110.
    Heinrich D, Kotitschke R, Berthold H. Clinical evaluation of the hepatitis safety of aβ-propiolactone/ultraviolet treated factor IX concentrate (PPSB). Thromb Res 1982;28:75–83.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • B. Rademaker
    • 1
  • J. Raber
    • 2
  1. 1.Department of PharmacologyAA WeespThe Netherlands
  2. 2.Department of VirologyThe Weizmann Institute of ScienceRehovotIsrael

Personalised recommendations